Gujarat Themis Biosyn to Acquire Sanofi's Global Anti-TB Portfolio for €158 Million
Gujarat Themis Biosyn will acquire Sanofi's global anti-TB and anti-infective portfolio for €158 million. The deal includes 13 brands across 55+ countries, with net sales of €62 million in FY25. This asset-light acquisition aims for forward integration and is expected to close by end of Q3FY27.
The acquisition is significant as it involves a substantial transaction value (€158 million) and expands the company's global footprint into over 55 countries, representing a major strategic shift and growth opportunity.
The acquisition of Sanofi's global portfolio is a strategic move that expands the company's global reach, strengthens its market position in anti-infectives, and is expected to be EPS accretive, indicating positive future prospects.
Gujarat Themis Biosyn Limited (GTBL) has entered into an asset purchase agreement to acquire Sanofi's global anti-tuberculosis (TB) and anti-infective portfolio. This strategic move aims to strengthen GTBL's global pharmaceuticals platform and expand its presence in the anti-infective segment, marking a step towards global forward integration.
The acquisition includes 13 established branded generic products with a presence in over 55 countries across Europe, the Middle East, and Africa. The portfolio reported net sales of approximately EURO 62 million for the year ended 2025. The transaction encompasses marketing authorizations, brands, regulatory dossiers, inventory, and associated commercial rights, but excludes manufacturing facilities and employees, positioning it as a capital-efficient, asset-light expansion.
This acquisition will provide GTBL with immediate access to regulated and semi-regulated markets, enhancing its international footprint. It also presents an opportunity for forward integration, leveraging GTBL's existing capabilities in fermentation-based intermediates and APIs to support the acquired finished dosage formulations. The portfolio currently operates at healthy gross margins, with potential for further improvement through backward integration and operational efficiencies.
Dr. Sachin Patel, Managing Director of GTBL, stated that this acquisition is a strategic milestone, transitioning the company towards a high-margin, fermentation-based pharmaceutical platform. He emphasized that controlling the process from fermentation to the final product minimizes supply chain risks and improves long-term profitability. The company expects to unlock further value through market expansion, new formulations, and optimization of distribution networks.
The consideration for the transaction is EURO 158 million, payable in cash at closing. This amount is expected to be funded by an optimal mix of debt and equity. The transaction is anticipated to be EPS accretive. The acquisition is scheduled to close by the end of Q3FY27 (Quarter Ending 31st December 2026), subject to customary closing conditions, including antitrust and foreign direct investment approvals.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.